Protection Against Ischemia/reperfusion–induced Renal Injury by Co–treatment with Erythropoietin and Sodium Selenite

Lu Liu,Chao Liu,Lan Hou,Juan Lv,Fang Wu,Xuefei Yang,Shuting Ren,Wenjun Ji,Meng Wang,Lina Chen

DOI: https://doi.org/10.3892/mmr.2015.4426

IF: 3.423

2015-01-01

Molecular Medicine Reports

Abstract:Ischemia/reperfusion injury (IRI) has lzong been an area of concern and focus of investigations. Erythropoietin (EPO) exhibits multiple protective effects, and selenium is an antioxidant trace element in the body, however, there have been no reports concerning the effects of EPO combined with sodium selenite on IRI. In the present study, a mouse model of renal IRI (RIRI) was pre-treated with EPO and sodium selenite to determine the most appropriate combination ratio of the two for further investigation. The results revealed that EPO and sodium selenite had synergistic protective effects in RIRI. EPO was identified as the predominant treatment component, with sodium selenite serving as an adjuvant, and combination treatment was markedly more effective, compared with treatment with either drug alone. The optimal ratio of treatment was 10:1 (10 IU EPO: 1 mu g sodium selenite). The results indicated that RIRI markedly induced renal injury, as evidenced by elevated levels of blood urea nitrogen (BUN), as well as higher pathological scores, based on hematoxylin and eosin staining. Pre-treatment with EPO and sodium selenite significantly decreased serum expression levels of BUN and malonaldehyde, and increased the expression levels of superoxide dismutase, glutathione peroxidase and nitric oxide (NO), compared with the model group. Furthermore, co treatment with EPO and sodium selenite upregulated the protein expression levels of phosphatidylinositol 3 kinase (PI3K) in renal tissue samples. Together, the results suggested that co administration of EPO and sodium selenite effectively ameliorates IRI induced renal injury by reducing oxidative stress and activating the PI3K/NO signaling pathway.